Fig 4.

Progression-free survival of 331 evaluable patients with Hodgkin lymphoma treated with response-adapted therapy on the Southwest Oncology Group S0816 trial. Patients were stratified by Deauville score assessed via centralized positron emission tomography (PET) review of the fluorodexoxyglucose-PET interim scan performed after two cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine. Only five patients had a Deauville score of 5 after two cycles of ABVD, so they are combined with the 55 patients with a Deauville score of 4.